Skip to content

Baduanjin Exercise for Patients With GOLD 2-3 Stable COPD on Pulmonary Rehabilitation

Baduanjin Exercise for Patients With GOLD 2-3 Stable Chronic Obstructive Pulmonary Disease on Pulmonary Rehabilitation: A Prospective, Randomized, Controlled Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03892629
Enrollment
240
Registered
2019-03-27
Start date
2019-04-30
Completion date
2019-12-31
Last updated
2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

Chronic Obstructive Pulmonary Disease (COPD) is a disease with a very high morbidity and mortality rate. When the lung function drops lower and lower, patients will bear great affliction physically and mentally. How to improve the quality of life in patients with COPD is a hot topic in the study of COPD now. Baduanjin, as one of the traditional Chinese qigong exercises, has the features of generous stretch, soft consistency, dynamic but static, which is an appropriate movement pattern for COPD patients.

Detailed description

To investigate the efficacy of Baduanjin exercise for patients with stable chronic obstructive pulmonary disease on phase II\ III. A prospective, randomized, controlled clinical trial was designed.

Interventions

Participants received Baduanjin exercise. Each Baduanjin exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks

DEVICEInstrument rehabilitation

Participants received pulmanory rehabilitation by using tri-ball respiratory trainer. Each instrument exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks

Sponsors

Shanghai Zhongshan Hospital
CollaboratorOTHER
ShuGuang Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Aged from 40 to 80 years * Diagnosed with stable chronic obstructive pulmonary disease * Phase II\ III

Exclusion criteria

* The condition was serious or movement restrained by other diseases * In the acute exacerbation of chronic obstructive pulmonary disease * Participants who have contraindications to exercise training * Patients who have other serious acute, chronic organic disease or mental disorders

Design outcomes

Primary

MeasureTime frameDescription
Six-minute walk test (6MWT)Baseline, 3 months, 6 monthsTesting patients changes on walking distance and accompanies symptoms in 6 minutes
St. George's respiratory questionnaire (SGRQ)Baseline, 3 months, 6 monthsEvaluating the changes of impact on quality of life

Secondary

MeasureTime frameDescription
Modified British medical research council questionnaire (mMRC)Baseline, 1 month, 2 months, 3 months, 6 monthsEvaluating the severity of dyspnea, totally has 5 grade from 0-4, the higher grade represent a severer symptom
COPD assessment test (CAT)Baseline, 1 month, 2 months, 3 months, 6 monthsAssessing the quality of life, the total score ranges from 0-40, the higher score represent a worse outcome
Self-rating anxiety scale (SAS)Baseline, 3 months, 6 monthsEvaluating the stage of anxiety, the total score ranges from 20-80, the higher score represent a worse outcome
Self-rating depression scale (SDS)Baseline, 3 months, 6 monthsEvaluating the stage of depression, the total score ranges from 20-80, the higher score represent a worse outcome
Times of acute exacerbationBaseline, 1 month, 2 months, 3 months, 6 monthsRecording the frequency of acute exacerbation
Pulmanory function indicators (FEV1/FVC, FEV1pred%)Baseline, 3 months, 6 monthsAssessing changes of airway limitation

Other

MeasureTime frameDescription
The main TCM symptomsBaseline, 1 month, 2 months, 3 months, 6 monthsThe changes of scores of TCM syndromes, the total score ranges from 0-15, the higher score represent a worse outcome

Countries

China

Contacts

Primary ContactMeng Sun, Master
gulik002@aliyun.com86-21-20256375

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026